Form 4 for CAI Caris Life Sciences, Inc.
Accepted 2026-09-04 16:59:59 ET · period of report 2026-09-03 · accession 0002071953-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-04 16:59 | 2026-09-03+ | CAI | Spetzler David Baxley | Pres | M - OptEx | $2.44 | +1.25M | 1.30M | +2,400% | +$3.05M |
| DM | 2026-09-04 16:59 | 2026-09-03+ | CAI | Spetzler David Baxley | Pres | S - Sale+OE | $24.84 | -597.2K | 1.18M | -34% | -$14.83M |
| DM | 2026-09-04 16:59 | 2026-09-03+ | CAI | Spetzler David Baxley | Pres | M - OptEx | $0.00 | -1.25M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-03 | M | A | 1,000,000 | $2.44 | 1,530,083 | D | — | — | |
| 2 | Common | Common Stock | 2026-09-03 | S | D | 393,100 | $24.76 | 1,136,983 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-09-03 | S | D | 84,900 | $25.32 | 1,052,083 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-09-04 | M | A | 250,000 | $2.44 | 1,302,083 | D | — | — | |
| 5 | Common | Common Stock | 2026-09-04 | S | D | 119,212 | $24.76 | 1,182,871 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Derivative | Stock Option | 2026-09-03 | M | D | 1,000,000 | $0.00 | 250,000 | D | $2.44 · — to 2026-09-12 | 1,000,000 Common Stock | (F5) Exercise of stock options before their expiration date. (F6) The stock option is fully vested and exercisable. |
| 7 | Derivative | Stock Option | 2026-09-04 | M | D | 250,000 | $0.00 | 0 | D | $2.44 · — to 2026-09-12 | 250,000 Common Stock | (F5) Exercise of stock options before their expiration date. (F6) The stock option is fully vested and exercisable. |